Treatment of osteopenia

Area of Science:

• Bone health and osteoporosis management.
• Clinical endocrinology and geriatrics.

Background:

• Osteoporotic fractures are common in individuals with bone mineral density (BMD) T-scores in the osteopenic range (-2.5 < T-score < -1).
• Current guidelines suggest caution regarding widespread anti-osteoporotic medication solely based on osteopenic T-scores.

Purpose of the Study:

• To evaluate the necessity and efficacy of anti-osteoporotic medication in individuals with osteopenia.
• To determine when osteopenia warrants specific osteoporosis therapy.

Main Methods:

• Analysis of fracture incidence in relation to BMD T-scores.
• Comparison of Number Needed to Treat (NNT) for anti-osteoporotic medications in osteopenic versus osteoporotic ranges.
• Review of treatment efficacy data for osteoporosis therapies in different BMD categories.
• Assessment of vertebral fractures using lateral X-rays from DXA (dual-energy X-ray absorptiometry) machines.

Main Results:

• The Number Needed to Treat (NNT) is significantly higher (NNT > 100) for treating osteopenia compared to treating established osteoporosis (NNT 10-20).
• The efficacy of specific osteoporosis treatments is less well-established in the osteopenic range compared to T-scores below -2.5.
• Osteopenia alone does not automatically necessitate osteoporosis treatment; it requires association with low-energy fractures or a high predicted fracture risk (e.g., via FRAX assessment).

Conclusions:

• Osteopenia, indicated by BMD T-scores between -1 and -2.5, does not inherently mandate anti-osteoporotic therapy.
• Treatment decisions for osteopenia should consider fracture history and calculated future fracture risk.
• Antiresorptive therapies are generally preferred for patients requiring treatment, with anabolic therapies reserved for rare cases.